Abstract. Salinomycin is a monocarboxylic polyether ionophore isolated from Streptomyces albus that has been used for more than 30 years as an agricultural antibiotic to prevent coccidiosis in poultry and to improve nutrient absorption and feed efficiency in ruminants and swine. As a inonophore with strict selectivety for alkali ions and a strong preference for potassium, salinomycin interferes with transmembrane potassium potential and promotes the efflux of K
Introduction
During the course of a screening program for new antibiotics in 1974, Miyazaki et al (1) isolated a new biologically active substance from the culture broth of Streptomyces albus (strain No. 80614) that was termed salinomycin. Salinomycin is a 751 da monocarboxylic polyether antibiotic that constitutes a large pentacyclic molecule with a unique tricyclic spiroketal ring system and an unsaturated six-membered ring (Fig. 1) . It is a lipophilic, anionic and weakly acidic compound with the molecular formula c 42 H 70 o 11 (1, 2) . Salinomycin acts in different biological membranes, including cytoplasmic and mitochondrial membranes, as a ionophore with strict selectivity for alkali ions and a strong preference for potassium, thereby promoting mitochondrial and cellular potassium efflux and inhibiting mitochondrial oxidative phosphorylation (3) (4) (5) .
Salinomycin has been shown to exhibit antimicrobial activity against gram-positive bacteria including mycobacteria and Staphylococcus aureus, some filamentous fungi, Plasmodium falciparum, and Eimeria spp., protozoan parasites responsible for the poultry disease coccidiosis (1, 6, 7) . Therefore, salinomycin has been used for more than 30 years as an effective anticoccidial drug in poultry (8) and is also fed to ruminants and pigs to improve nutrient absorption and feed efficiency (9) (10) (11) .
in addition to its versatile antimicrobial activitiy, salinomycin is a positive ionotropic and chronotropic agent that increases cardiac output, left ventricular systolic pressure, heart rate, mean arterial pressure, coronary artery vasodilatation and blood flow, and plasma catecholamine concentrations as demonstrated in dogs receiving an intravenous injection of 150 µg•kg -1 salinomycin (12). However, salinomycin has never been used as a drug in humans, probably due to the considerable toxicity observed in mammals (13-16).
Effects of salinomycin on human cancer stem cells
Cancer stem cells comprise a unique subpopulation of tumor cells that possess tumor initiation and self-renewal capacity and the ability to give rise to the heterogeneous lineages of cancer cells that make up the bulk of the tumor (17) (18) (19) . Cancer stem cells have been identified in a variety of human neoplasias, including cancers of the blood, breast, brain, bone, skin, liver, bladder, ovary, prostate, colon and pancreas (19, 20) . cancer stem cells display numerous mechanisms of resistance to chemotherapeutic drugs and irradiation therapy, allowing them to survive current cancer therapies and to initiate longterm tumor recurrence and metastasis (21, 22) .
of note, Gupta et al (23) demonstrated that salinomycin selectively kills human breast cancer stem cells in vitro. In a complex experimental system, the authors used oncogenic transformed immortalized human mammary epithelial cells (HMLEr), in which knockdown of E-cadherin by rNA interference resulted in the generation of cells undergoing epithelial-mesenchymal transition (eMT) and displaying characteristic properties of cancer stem cells (24) (25) (26) . These human breast cancer stem-like cells, termed HMLEr-shEcad, are capable of forming tumorspheres in suspension cultures, show high and low expression of CD44 and CD24, respectively, and exhibit resistance to chemotherapeutic drugs and cytotoxic agents such as paclitaxel, doxorubicin, actinomycin D, campthotecin and staurosporine (23) .
in a robotic high-throughput screening approach, about 16,000 compounds from chemical libraries, including biological molecules and natural extracts, were tested for activity against HMler-shecad cells and control cells that had not undergone EMT (23) . only one compound markedly and selectively reduced the viabililty of stem-like HMLEr-shEcad cells: salinomycin. In subsequent experiments, it was demonstrated that salinomycin, in contrast to the chemotherapeutic drug paclitaxel, selectively reduces the proportion of cd44 high / cd24 low stem-like cells in cultures of mixed populations of HMler-shecad cells and control cells that had not undergone EMT. Moreover, pre-treatment of HMLEr-shEcad cells with salinomycin resulted in inhibition of HMLEr-shEcadinduced tumorsphere formation, which was not observed after pre-treatment of the cells with paclitaxel (23) .
Global gene expression profiling was employed to show that, in cd44 high /CD24 low HMler cells, salinomycin, but not paclitaxel, was capable of changing a gene expression signature characteristic of breast cancer stem cells and mammary epithelial progenitor cells isolated from human tumors. For example, expression of genes that inversely correlates with metastasis-free survival and overall survival of breast cancer patients (27, 28) was down-regulated by salinomycin (23) . Expression of a set of genes that promote the expansion of mammary epithelial stem cells and the formation of mammospheres (29) was also markedly down-regulated by salinomycin (23) . By contrast, genes probably involved in mammary epithelial differentiation that encode membrane-associated or secreted proteins as components of the extracellular matrix were up-regulated by salinomycin (23) .
As a proof of principle, it was demonstrated that salinomycin inhibits the ability of breast cancer stem-like cells to form tumors in mice. Pre-treatment of HMLEr cells for seven days with salinomycin and subsequent injection of the cells into NoD/SCID mice resulted in a >100-fold decrease in tumor-seeding ability, relative to pre-treatment of the cells with paclitaxel. Finally, salinomycin treatment of NoD/SCID mice with breast cancer tumors established by injection of human breast cancer cells resulted in a reduction of the tumor mass and metastasis, and explanted tumors showed a reduced number of breast cancer stem cells (Fig. 2) as well as an increased epithelial differentiation (23) .
in addition, a recent study demonstrated that salinomycin was capable of overcoming ATP-binding cassette (ABC) transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like cells (30) . one of the most important mechanisms of drug resistance in leukemia stem cells and other cancer stem cells is the expression of ABC transporters belonging to a highly conserved superfamily of transmembrane proteins capable of exporting a wide variety of molecules and structurally unrelated chemotherapeutic drugs from the cytosol, thereby conferring multidrug resistance, which is a major obstacle to the success of cancer chemotherapy (31) (32) (33) . As shown in the study, expression of functional ABC transporters such as P-glycoprtein, BCrP and MrP8 confers resistance of human KG-1a leukemia stem cell-like cells to a broad spectrum of chemotherapeutic drugs including the proteasome inhibitor bortezomib, but not to salinomycin (Fig. 3) . Moreover, salinomycin does not permit long-term adaptation of KG-1a cells to apoptosis-inducing concentrations, whereas the cells can be adapted to proliferate in the presence of apoptosis-inducing concentrations of bortezomib and doxorubicin (30) .
All these findings strongly suggest that salinomycin is a selective killer of human cancer stem cells and a new promising agent for the elimination of cancer stem cells.
Effects of salinomycin on human cancer cells
a recent study revealed that salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells of different origins (34) . First, it was demonstrated that salinomycin at doses lower than those used by Gupta et al induced massive apoptosis in cd4 + T-cell leukemia cells isolated from patients with acute T-cell leukemia (Fig. 4) . Notably, salinomycin failed to induce apoptosis in normal cd4 + T cells isolated from healthy humans (Fig. 4) , suggesting that salinomycin selectively kills malignant cells. Secondly, various human leukemia and lymphoma cells were shown to undergo apoptosis in response to treatment with salinomycin.
Since the induction of p53-mediated apoptosis is a central mechanism of the cytotoxicity of many anticancer drugs (35, 36) , lymphoblastic leukemia cell types expressing a functional (wild-type) tumor suppressor protein p53 or lacking p53 expression due to a homozygous nonsense mutation in the p53 gene were investigated. It was shown that salinomycin is capable of inducing apoptosis in both wild-type p53 cells and p53-lacking cells, indicating that the induction of apoptosis by salinomycin is independent of the p53 status of the cell (34) . Next, p53-lacking lymphoblastic leukemia cells were transfected with a plasmid encoding the human anti-apoptotic protein Bcl-2, leading to stable overexpression of Bcl-2 and resistance of the cells to apoptosis induced by chemotherapeutic drugs (37) . In these cells, salinomycin was able to markedly induce apoptosis even at the low concentrations used for the induction of apoptosis in non-resistant cells (34) . other types of human cancer cells displaying multidrug resistance and general resistance to apoptosis induced by chemotherapeutic drugs, cytotoxic agents and γ-irradiation were investigated for their ability to undergo apoptosis in response to salinomycin treatment. For example, human Burkitt lymphoma cells, which exhibit apoptosis resistance and hyperproliferation due to the increased expression and proteolytic activity of 26S proteasomes in response to adaptation to lethal concentrations of the proteasome inhibitor bortezomib (38) , undergo massive apoptosis in response to treatment with salinomycin at low doses effective in nonresistant cells (34) . Moreover, human uterine sarcoma cells, which display resistance to a large panel of chemotherapeutic drugs by virtue of the expression of P-glycoprotein, a transmembrane efflux pump that eliminates various drugs and small molecules from the cytosol (39-41), undergo apoptosis in response to salinomycin treatment (34) . Salinomycin activates a distinct and unconventional pathway of apoptosis in cancer cells that is not accompanied by cell cycle arrest, and that is independent of tumor suppressor protein p53, caspase activation, the CD95/DC95 ligand system and the 26S proteasome (34) . This might be one reason why salinomycin can overcome multiple mechanisms of drug and apoptosis resistance in human cancer cells. Many cancer cells harbor or acquire multiple mechanisms of apoptosis resistance mediated by the loss of p53 and overexpression of Bcl-2, P-glycoprotein or 26S proteasomes with enhanced proteolytic activity (42) (43) (44) . Salinomycin, however, appears to be capable of overcoming these mechanisms of drug and apoptosis resistance, suggesting a possible future use of salinomycin in the treatment of drug-resistant and aggressive cancers. 
A B 4. Conclusion and perspective
Salinomycin is a well defined agricultural antibiotic that has been used for more than 30 years in the prevention of coccidiosis in poultry and for improving nutrient absorption and feed efficiency in ruminants and swine. A notable recent discovery was that salinomycin selectively kills human cancer stem cells, inhibits breast cancer growth and metastasis in mice and induces massive apoptosis in various apoptosis-resistant human cancer cells. Cancer stem cells are known to exhibit resistance to a broad spectrum of chemotherapeutic drugs, thereby surviving current cancer therapies and initiating long-term tumor recurrence, relapse and metastasis (21, 22) . development of multiple mechanisms of drug and apoptosis resistance is a hallmark of aggressive, advanced and recurrent cancer (45, 46) . It is intriguing that both cancer stem cells and apoptosis-resistant cancer cells are effectively killed by salinomycin, although at present only in vitro. The exact mechanism of salinomycin-induced apoptosis remains unclear, but it appears that salinomycin activates an unconventional pathway of apoptosis that may contribute to the breakdown of apoptosis resistance in cancer cells. Salinomycin is a potassium ionophore that interferes with transmembrane potassium potential and promotes the efflux of K + ions from mitochondria and cytoplasm. A decrease in intracellular potassium concentration has previously been shown to be essential for the induction of apoptosis in human lymphoma cells (47) , suggesting that salinomycin-induced apoptosis is mediated, at least in part, by the ability of salinomycin to deplete cytoplasmic and mitochondrial potassium and/or to interfere with potassium membrane potential. Potassium channels of the mitochondrial and cytoplasmic membrane are overexpressed in many human cancer cells, play pivotal roles in the regulation of tumorigenesis, tumor cell proliferation, cell cycle progression and apoptosis (48) (49) (50) , and may constitute novel and promising molecular targets for cancer therapy (51) . Now that the potassium ionophore antibiotic salinomycin has been shown to kill human breast cancer stem cells and apoptosisresistant cancer cells in vitro, the investigation of its safety, toxicity, pharmacology and anticancer activity in humans is a challenge for the coming years.
